Speakers

John D’Angelo, MD, is CEO-elect of Northwell Health, effective October 1, 2025 and the Executive Vice President, Market President for Northwell Health’s Central Market, which includes North Shore University Hospital, Long Island Jewish Medical Center, Cohen Children’s Medical Center, LIJ Forest Hills Hospital, LIJ Valley Stream Hospital and Zucker Hillside Hospital, as well as Northwell’s 260+ ambulatory locations within the Nassau/Queens area.

Dr. D’Angelo led Northwell’s operational response to the COVID-19 pandemic as Operations Chief for the system command center and was later appointed Chief of Integrated Operations. Leveraging lessons from the pandemic, he integrates Northwell’s extensive operational resources in the post-pandemic era. Previously, as Senior Vice President and Executive Director of Northwell Health’s Emergency Medicine Service Line, he oversaw the clinical and operational performance of Northwell’s emergency departments, observation units, and a growing network of urgent care centers, serving nearly 1.5 million patients annually.

As an Emergency Medicine physician for over 25 years, Dr. D’Angelo has a keen understanding of clinical care delivery, quality, process improvement and operations management. He has spearheaded numerous initiatives that have distinguished Northwell over the years. Examples of his work include Northwell’s sepsis efforts, which earned The Joint Commission’s Eisenberg Award, the opening of Manhattan’s first free-standing emergency department, Lenox Health Greenwich Village.

A leader in data transparency and access, Dr. D’Angelo co-led the creation of Real-Time Actionable Data, enhancing operational data visibility for leaders and frontline staff across Northwell. This innovation earned Northwell’s top award in 2019. The team’s solutions have significantly expanded, playing a crucial role in the COVID-19 response and culminating in a comprehensive hospital command center suite at North Shore University Hospital.

Dr. D’Angelo has served as the Chair for the Northwell Health Physician Partners Board of Governors & Executive Committee from 2019 -2022. He is also an Associate Professor of Emergency Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

A Long Island native, Dr. D’Angelo received his medical degree from SUNY Stony Brook and subsequently completed a residency in Emergency Medicine at Geisinger Medical Center, Danville, PA. He started his career as an attending at Holyoke Hospital in Massachusetts and transitioned to an attending physician at Northwell Health’s Glen Cove Hospital in 2000 and appointed Chair of the Glen Cove’s Emergency Department in 2005. He also served as medical director to numerous EMS agencies throughout his career and served in the United States Army Reserve from 2001-2011.

Ami B. Bhatt, MD, FACC, is the Chief Innovation Officer of the American College of Cardiology, where she leads initiatives at the intersection of clinical practice, emerging technologies, and health policy. She earned her undergraduate degree from Harvard University and her medical degree from the Yale School of Medicine.

Dr. Bhatt is recognized nationally for her leadership in advancing the AI-enabled clinician, promoting equitable and scalable technology adoption, and guiding investments in transformative healthcare solutions. With over two decades of experience as a practicing cardiologist, clinical investigator, and educator, she brings deep expertise in care delivery and digital transformation.

At Massachusetts General Hospital, Dr. Bhatt served as Director of Outpatient Cardiology, Telecardiology, and Adult Congenital Heart Disease, and held the position of Associate Professor of Medicine at Harvard Medical School. Her research portfolio spans basic science, physiology, clinical trials, and outcomes research, encompassing investigator-initiated and industry-sponsored studies. She also co-designed the MGH Elevate Leadership Program to cultivate communication, adaptability, and innovation among future medical leaders.

A widely published author and sought-after speaker, Dr. Bhatt has delivered keynote addresses around the world, including TEDx talks, and contributes regularly to scholarly and public discourse on cardiovascular innovation and the physician’s evolving role. Dr. Bhatt advises startups and established companies in AI, digital health, and diagnostics on clinical integration, market strategy, and scalable implementation. She works with boards, investors, and cross-sector partners to align innovation with clinical relevance, regulatory strategy, and long-term value creation.

Dr. Bhatt chairs the FDA Digital Health Advisory Committee and led its inaugural meeting on generative AI and regulatory frameworks. She also advises the FDA’s TAP program for breakthrough devices and provides strategic input to the Consumer Technology Association, the U.S. Government Accountability Office, and other governmental, nonprofit, and industry organizations. She most recently spoke on AI in Healthcare at the World Economic Forum in Davos, Switzerland.

Leonard Calabrese is a Professor of Medicine, Vice Chair of the Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases and the Co-director of the Centre for Vasculitis Care and Research. He also serves as Director of the RJ Fasenmyer Centre for Clinical Immunology at the Cleveland Clinic. He also holds appointments in the Department of Infectious Diseases and the Wellness Institute.  

He has particular interest in vascular inflammatory disease of the central nervous system, primary and secondary immunodeficiency states and the intersection of infections and autoimmunity. Over the course of his academic research career, Professor Calabrese has authored over 500 publications including book chapters and peer-reviewed journal articles.   

Kris is the President & CEO of Galvani Bioelectronics, overall responsible for the company’s path to and delivery of bioelectronic medicines to patients. He has led the UK and US-based company since its inception in 2016, building its strategy, organisation, novel therapy platform and clinical-stage pipeline as the pioneer and frontrunner in near-organ bioelectronics. Before his appointment to lead Galvani, he was the founding VP and Head of Bioelectronics R&D at GSK, which he launched in 2013. There he managed the unit’s extensive research towards establishing the treatment potential, disease reach, and technology requirements for bioelectronic medicines, working together with a network of research partners across academia and industry. During his time at GSK, he also headed up the R&D strategy group and the Protein Degradation Discovery Performance unit – the first industry unit to pursue protein degradation as a therapeutic modality. Kris obtained his PhD in Molecular Biology at University of Cambridge under the supervision of Nobel Laureate Sir Greg Winter, following a MSc in Chemical Engineering at Lund University, Sweden. Before joining GSK in 2009, he was an engagement manger working across the biopharma industry at McKinsey & Company. 

Scott Gottlieb, MD, is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. He is currently a senior fellow at the American Enterprise Institute for Public Policy Research and a partner at the venture capital firm New Enterprise Associates.

Under his leadership, the FDA advanced new frameworks for the modern oversight of gene therapies, cell-based medicines, and digital health devices. The agency implemented new reforms to standardize drug reviews and made historic improvements in post-market data collection and the use of real-world evidence. He promoted policies to reduce death and disease from tobacco, improve food safety, and aggressively confront addiction crises. The agency’s prolific advances in new policy distinguished his tenure as FDA Commissioner, along with a record-setting number of approvals for novel drugs, medical devices, and generic medicines.

Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and, before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services. He is the author of the New York Times bestselling book “Uncontrolled Spread: Why Covid-19 Crushed Us and How We Can Defeat the Next Pandemic” and is a regular contributor to CNBC and CBS News’ Face the Nation. Dr. Gottlieb serves on the board of directors of publicly traded companies Pfizer, Inc., Illumina, Inc., and TempusAI.

Dr. Gottlieb is an elected member of the National Academy of Medicine and completed medical school and a residency in internal medicine at the Mount Sinai School of Medicine, where he currently serves on the executive committee of the Mount Sinai Health System’s board of directors and co-chairs the board’s education committee. He graduated from Wesleyan University, where he majored in economics, and currently serves on the university’s board of directors. Dr. Gottlieb lives in Connecticut with his wife and three daughters.

Jill Kalman joined Northwell in May 2014 as associate medical director in the office of the chief medical officer, and as the associate medical director at Long Island Jewish Medical Center. She later served as executive director and medical director of Lenox Hill Hospital, where she was responsible for the quality of patient care, safety and day-to-day operations.

Under Dr. Kalman’s leadership, Lenox Hill elevated its reputation as a regional, national and global destination for top quality tertiary care. She and her team significantly expanded the breadth of clinical programs, successfully recruited top physicians and grew patient volume. She was instrumental in leading the Lenox Hill response to the COVID-19 pandemic and its recovery efforts while driving employee engagement to the 91st percentile. Lenox Hill also received coveted Magnet status in 2020 for its commitment to nursing excellence. 

Dr. Kalman is an expert in congestive heart failure and has tremendous experience managing patients with advanced heart disease. She has been published extensively on the subject and has dedicated her career to improving the quality of life for patients at all stages of heart disease. 

After graduating with honors from the University of Pennsylvania, Dr. Kalman received her medical degree from the Mount Sinai School of Medicine. She completed her internal medicine residency, chief residency and cardiology fellowship at the Mount Sinai Medical Center, including a research fellowship in heart failure and cardiac transplantation. 

Michael Koeris, PhD, joined DARPA as the director of the Biological Technologies Office in April 2024. 

His research and teaching focus on all aspects of chemistry, manufacturing, and control for microbiome medicines, as well as advanced cell and gene therapy approaches.

Before coming to DARPA, Koeris served as professor of bioprocessing and as a member of the Amgen Bioprocessing Center in the Department of Biological Engineering and Management at the Keck Graduate Institute.  

He also advised the NIH’s RADx initiative as a Portfolio Executive, assisting with the rapid development, clinical validation, manufacturing and distribution of Sars-CoV-2 diagnostic tests throughout the pandemic. Prior to joining KGI in 2020, Koeris actively started, grew, and exited biotechnology startups, both as founder and senior leader, as well as a member of the Board of Directors. He holds more than a dozen patents through the U.S. and internationally. His entrepreneurial career began by spinning out Sample6, which was recognized by Forbes as one of the 25 hottest AgTech startups in 2017 and was acquired later that year.  

Koeris serves as a Board Director of global, non-profit repository AddGene, and in the past served on boards of commercial biotech entities. 

Education 

• PhD, Biomedical Engineering, Boston University 

• MS, Biochemistry and Biophysics, Free University of Berlin, Germany 

• BS, Biochemistry and Biophysics, Free University of Berlin, Germany 

Dr. Hubert Lim is a Professor in the Biomedical Engineering and Otolaryngology Departments at the University of Minnesota and was hired as an Institute for Translational Neuroscience Scholar. He is also the Endowed Lions Professor in Otolaryngology, Director of the Earl E. Bakken Medical Devices Center, IEM Associate Director of Innovation, and Co-Director for the Center for Neural Engineering. He completed a B.S.E. in Bioengineering at UC-San Diego, followed by a dual Masters in Biomedical Engineering and Electrical Engineering & Computer Science and then a Ph.D. in Biomedical Engineering at the University of Michigan.  

His research focuses on neural engineering, medical devices, sensory neuroscience, neural plasticity, neuro-immune physiology, and integrative health approaches with the aim of developing new stimulation treatments for hearing disorders, pain, and inflammatory conditions in collaboration with multiple clinicians and companies. 

Beyond his academic activities, he is involved with three start-up companies, serving as the Chief Scientific Officer of Neuromod Devices (developing a tinnitus treatment device), Chief Scientific Officer of SecondWave Systems (developing a wearable phased-array ultrasound device for various health conditions), and Chief Technology Officer of NeoAcoustics (developing new types of audio-based technologies for consumer and health applications). 

Dr. Geoffrey Ling is a pharmacologist and physician and co-founder of On Demand Pharmaceuticals. Clinically, he is a professor of neurology, neurosurgery and anesthesiology and critical care medicine at Johns Hopkins University and the Uniformed Services University of the Health Sciences, and an attending neuro critical care physician at Johns Hopkins Hospital. He serves as the Chair of the Veterans Administration’s National Research Advisory Council.

Dr. Ling is a retired U.S. Army colonel after 21 years on active duty. He served as an intensive care physician with the 452nd CSH (combat support hospital) in OEF-Afghanistan (2003) and 86th CSH and 10th CSH in OIF-Iraq (2005). Also, COL Ling has had four in-theater missions as a member of the Joint Chiefs of Staff “Gray Team” to assess traumatic brain injury (TBI) care in both combat theaters (2009, 2011). The 10th CSH named him their first “Physician of the Month.” Dr. Ling was also a “requested by name” consultant to Congresswoman Gabby Gifford’s trauma team following her tragic attack.

He was the Founding Director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA), where he was previously a program manager and Deputy Director of the Defense Sciences Office. He served as an Assistant Director in the Science Division of President Obama’s White House Office of Science, Technology and Policy (OSTP). His BA with honors is from Washington University in St. Louis, MD from Georgetown University (elected to AOA) and his PhD in neuropharmacology is from Cornell University. He completed his neurology residency at Walter Reed Army Medical Center, neuro critical care fellowship at Johns Hopkins and research fellowship in neuropharmacology at the Memorial Sloan Kettering Cancer Center. He is board certified in both neurology and neuro critical care. He has published more than 200 peer-reviewed articles and book chapters.

Josh Makower is the Yock Family Professor of Medicine and Bioengineering at the Stanford University Schools of Medicine and Engineering, and is the Byers Family Director and Co-Founder of the Stanford Mussallem Center for Biodesign.  Josh is the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 10 companies over the past 20 years. He is also a Senior Advisor to Patient Square Capital, and an Advisory Venture Partner with Sofinnova Partners. Josh currently serves on the boards of Elevage, ExploraMed, Moximed, Willow, X9, Coravin, SetPoint Medical and VentureWell.  

Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, plastic surgery, dermatology, aesthetics, obesity, orthopedics, women’s health, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT.  Josh is a Member of the National Academy of Engineering, a Fellow of The National Academy of Inventors and The American Institute for Medical and Biological Engineering, was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018 and was awarded an Honorary Doctorate of Science from the University of Galway in 2024 for his work supporting and inspiring the creation of BioInnovate Ireland which has had a profound impact on the Irish Medtech Innovation Ecosystem. 

Juan-Pablo is a partner at APVC in Santa Cruz, CA. He represents APVC on the Boards of Alpheus Medical, Cala Health, Exo Imaging, Neuspera Medical, Presidio Medical, Saluda Medical, SetPoint Medical, Onc.ai and previously CVRx (NASDAQ: CVRX). He was a founding team member and investor at Lightstone Ventures, and an investor at Morgenthaler Ventures, where he was a Board observer at Ardian (acq. by Medtronic), Twelve (acq. by Medtronic), Nuvaira, Cabochon Aesthetics (acq. by Ulthera/Merz), and Miramar Labs (acq. by Sientra). 

Prior to investing, Juan-Pablo led efforts in R&D and Strategy in Medtronic’s CardioVascular Division. He was named “Medtronic Inventor of The Year”. Subsequently, he was on the Global Brand Strategy team at Eli Lilly within the Cardiovascular business. 

Juan-Pablo earned an MBA and an M.S. in Electrical Engineering from Stanford University, and a B.S. in Electrical Engineering from the University of Massachusetts. He serves on Stanford’s Neuroscience Institute Oversight Committee, the Advisory Board for UCSF’s Rosenman Institute, the Investor Advisory Committee of AdvaMed, and is a founding Board Member of SomosVC which is dedicated to increasing the representation and advancement of Latino and Latina VCs across industry verticals. Juan-Pablo previously served eight years on the Board of InnerCity Weightlifting, a non-profit reducing youth violence and incarceration rates by fostering social inclusion and economic mobility. He played Division I men’s lacrosse at the University of Massachusetts, serves on the Board of USA Lacrosse since 2023, and is originally from Puerto Rico. 

Tyler Mathisen is one of the nation’s most respected business news journalists and interviewers. For more than 27 years, he was a news anchor and co-anchor for CNBC, the world’s top business news television channel. In that time he hosted or co-hosted virtually every program on the CNBC schedule, most recently “Power Lunch,” one of the network’s longest running program franchises. His coverage credits include: the bursting of the so-called “tech bubble” in 2000 the 9-11 terror attacks; the financial crisis of 2007-2009; and the Covid-19 pandemic and its profound business impact. Additionally, he was CNBC’s Vice President of Events Strategy. In that role, he helped map the company’s initiatives in the live events business, virtual and in person.  

Previously, Mathisen was Managing Editor of CNBC Business News, responsible for directing the network’s daily content and coverage, and Vice President for Strategic Editorial Initiatives.  

He also co-anchored “Nightly Business Report,” an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW).   

Mathisen also reported multiple one-hour documentaries for the network including “Best Buy: The Big Box Fights Back,” “Supermarkets Inc: Inside a $500 Billion Money Machine” and “Death: It’s a Living,” which won SABEW’s 2014 “Best in Business” award for best radio/TV feature or field report. He was also the host and chief correspondent of two CNBC series, “How I Made My Millions” and “High Net Worth.”  

His interview credits run from businesspeople (Bill Gates, Warren Buffett, Steve Jobs, Mark Cuban) to sports figures (Peyton Manning, Shaquille O’Neal, Mike Krzyzewski) to political players such as Treasury Secretaries Robert Rubin, Lawrence Summers and Timothy Geithner. He also interviewed then-businessman Donald Trump.  

In addition to his television work, on air and in management, he is a sought-after speaker, moderator, event emcee. Currently he is developing, in association with the University of Chicago’s Graham School, a lecture-and-conversation series called “Enduring Excellence.” Through on-stage and virtual interviews as well as lectures from eminent scholars, it explores how extraordinary individuals in business, sport and culture have been able to create careers and cultures of excellence spanning decades. 

Before joining CNBC in 1997, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. He also served as Money Editor for ABC’s “Good Morning America” from 1991 to 1997.  

A native of Arlington, Va., Mathisen graduated with distinction with a degree in government and foreign affairs from the University of Virginia.  

Scott Rechler is the CEO and Chairman of RXR, a fully integrated real estate company and investment manager that owns and manages over 30 million square feet of commercial properties and more than 9,600 multifamily units.  RXR specializes in public-private partnerships and master developments that include the $4 billion development of Terminal 6 at JFK International Airport, and a 1,100-acre, $3 billion mixed-use development in Raleigh, North Carolina. RXR also operates a billion-dollar credit platform that leverages its real estate expertise for various commercial real estate lending products. RXR’s expanding geographical footprint extends beyond the New York metropolitan region into some of the nation’s fastest-growing markets, such as Phoenix, Denver, Dallas, Raleigh, and Tampa. 

Before launching RXR, Scott was the Chair and CEO of Reckson Associates Realty Corp (NYSE: RA), a company he helped take public in 1995. RXR was founded in 2007, the day after Scott and his partners sold Reckson Associates to SL Green (NYSE: SLG) for over $6 billion, generating a 700% return for Reckson’s investors (assumes reinvestment of all dividends). Since its founding, RXR has raised over $10 billion in private equity and built an integrated team of more than 415 professionals with expertise in operations, construction and development, investment management, and more.  

Scott is currently serving his second three-year term on the Board of the Federal Reserve Bank of New York, which oversees the Second Federal Reserve District, the largest Reserve Bank in terms of assets and activity volume. He is a member of the bank’s Audit and Risk Committee, which assesses the adequacy and effectiveness of controls over financial reporting and the bank’s compliance with legal and regulatory requirements, including its responsibilities for executing operational activities related to monetary policy. 

From 2011 to 2016, Scott served as Vice Chairman of the Board for the Port Authority of New York and New Jersey, the country’s largest bi-state authority. During this tenure, he chaired the organization’s committee on Capital Planning, Execution, and Asset Management, guiding the authority to become a national leader in public-private partnerships through the award-winning transformation of LaGuardia Airport, the replacement of the Goethals Bridge, and the redevelopment of the World Trade Center complex. Scott also shaped the authority’s over $30 billion ten-year capital plan. 

From 2017 to 2019, Scott served on the Board of the Metropolitan Transportation Authority (MTA), the largest public transportation provider in North America, where he led the agency’s cost containment working group, implementing efficiency measures within the capital planning program. 

From 2017 to 2023, Scott served as the Chair of the Regional Plan Association (RPA), an independent non-profit civic organization that develops and promotes ideas to improve the economic health and quality of life in the New York metropolitan area.  

Scott also served on the Board of American Campus Communities (NYSE: ACC) after Reckson acquired a controlling interest in the company in 1998 and later took the company public in 2004. ACC became the largest student housing company in the United States and was acquired by Blackstone for $13 billion in 2022. 

Scott currently serves as a trustee and Vice Chair of the National September 11th Memorial and Museum and is on the Board of Trustees of New York University (NYU). He is actively engaged with several of the region’s top healthcare systems, serving as Chair of The Feinstein Institute for Medical Research and being a member of the Board at Northwell Health, as well as the Board of the Hospital for Special Surgery (HSS). Additionally, Scott is an active board member of the Real Estate Roundtable (RER) and the Real Estate Board of New York (REBNY).  

Amaza Reitmeier is a visionary healthcare executive with over 20 years of experience in MedTech. With a deep passion for transforming lives through innovation, Amaza spearheads the newly established Global Brain Health Solutions team—an enterprise-wide initiative aimed at positioning Medtronic as the world’s leading brain health company. Her work is driven by a bold vision to shape the future of brain health through sensing-enabled therapies, groundbreaking partnerships, and a long-term innovation roadmap that transforms care for people with neurological disorders. 

Amaza’s approach blends clinical insight, market foresight, and human-centered design. She and her team are leading the transformation of Deep Brain Stimulation (DBS) therapy through the global expansion of BrainSense™ technology, the world’s first commercial scale Brain Computer Interface (BCI) system. This technology redefines how brain signals are captured and used to personalize therapy through adaptive DBS (aDBS).  

Her leadership is marked by a commitment to collaboration, equity, and purpose—ensuring that every advancement in brain health is grounded in real-world benefit to patients and their families. 

Amaza earned an MBA from the Carlson School of Management’s Medical Industry Leadership Institute and a BA from Hamline University. She is a passionate advocate for career development in the MedTech industry and serves as an Executive Sponsor for Medtronic’s African Descent Network, Women’s Network, PRIDE Network and ASPIRE Sales Network. 

Dr. Zack Scott previously served on the board of directors for Cianna Medical, Coherex Medical, Evidation Health, Providence Medical Technology, Respicardia, Spiration, and Syapse. 

Prior to joining Norwest, Zack was the co-founder and managing partner of Revelation Partners, a dedicated secondary investor specializing in shareholder liquidity and growth capital for healthcare companies. During his time at Revelation Partners, he made notable investments in Omada Health, iRhythm Technologies (IPO), SetPoint Medical, and Respicardia (acquired by Zoll Medical). 

Before working in private equity, Zack was a General Surgery resident at Oregon Health & Science University in Portland, Oregon. He earned his M.D. from the University of Texas Health Science Center at San Antonio where he was a member of the AOA Medical Honors Society, and subsequently earned an M.B.A. with a specialized certificate in Health Sector Management from The Fuqua School of Business at Duke University where he was a Fuqua Scholar. 

Murthy Simhambhatla joined SetPoint Medical from Evolus, a medical aesthetics company with a lead biologic drug, DWP‐450, which he led towards an IPO in 2018. Prior to Evolus, Murthy was Senior Vice President at Abbott Laboratories and President of Abbott Medical Optics (AMO), a $1B‐plus global ophthalmic business focused on cataract and refractive surgery.

Prior to AMO, Murthy led the Ibis Biosciences molecular diagnostics business at Abbott. He joined Ibis after leading Abbott Vascular’s commercial operations in Australia and New Zealand. Murthy joined Abbott through the acquisition of Guidant’s vascular business, where he led the development of the Xience V Drug Eluting Stent, which remains the leading vascular stent platform globally.

Murthy has M.S. and Ph.D. degrees in Polymer Engineering from the University of Akron and a bachelor’s degree in Chemical Engineering from Anna University in India.

Kevin J. Tracey, is President and CEO and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research; Professor of Neurosurgery and Molecular Medicine at the Zucker School of Medicine at Hofstra-Northwell; and Executive Vice President, Research, at Northwell Health, in New York. A leader in the scientific fields of inflammation and bioelectronic medicine, his contributions include discovery and molecular mapping neural circuits controlling immunity and identifying the therapeutic action of monoclonal anti-TNF antibodies.

Professor Tracey received his B.S. (Chemistry, summa cum laude, Phi Beta Kappa) from Boston College in 1979, and his M.D. from Boston University in 1983.  He trained in neurosurgery from 1983 to 1992 at the New York Hospital-Cornell University Medical Center and was a guest investigator at the Rockefeller University before moving in 1992 to The Feinstein Institutes.

An inventor with more than 75 United States patents, author of more than 400 scientific publications, he cofounded the Global Sepsis Alliance, a non-profit organization supporting the efforts of >1 million sepsis caregivers in more than 70 countries. His honors and awards include a Doctorates honoris causa from the Karolinska Institute, Stockholm, Sweden, the University of Fribourg, Switzerland and Hofstra University, New York; the Boston University Distinguished Alumni Award; Fellow of the AIMBE Class (2020), the Harvey Society lecture, New York; and lectureships from Harvard, Yale, Rockefeller University, the NIH, and elsewhere. His memberships include the American Society of Clinical Investigation (2001), the American Association of Physicians (2009), the Long Island Technology Hall of Fame (2012), Alpha Omega Alpha (2014), the American Association for the Advancement of Science (2014), and the American Institute for Medical and Biological Engineering (2020). Professor Tracey is author of Fatal Sequence (Dana Press), and delivers lectures nationally and internationally on inflammation, sepsis, the neuroscience of immunity, and bioelectronic medicine.